The Compensation Committee granted CEO Gregory A. Demopulos a performance-based stock option award for up to 500,000 shares under the Company’s Omnibus Incentive Compensation Plan. The award carries an exercise price of $17.88 per share and vests based on four stock-price hurdles ranging from $25.00 to $40.00 over a five-year term, alongside continued-service conditions. This grant recognizes Dr. Demopulos' achievements in 2025, including FDA approval for YARTEMLEA and the sale of zaltenibart to Novo Nordisk. Omeros Corporation is a biopharmaceutical company focused on developing therapies for inflammatory diseases.
